Cimetidine tablets

1. Pharmacology: It mainly acts on H2 receptors on parietal cells, competitively inhibiting histamine. It can inhibit basal gastric acid secretion. It can also inhibit gastric acid secretion stimulated by food, histamine, pentagastrin, caffeine and insulin. 2. Toxicology: Acute toxicity, oral LD50 for mice is 3190-3280 mg/Kg, and oral LD50 for rats is 5840-7500 mg/Kg. Subacute and chronic toxicity tests on rats and dogs have shown that this product has a mild anti-androgen effect and can cause a decrease in the weight of the prostate and seminal vesicles. Milk secretion occurs, but disappears after drug withdrawal. It has no mutagenic, carcinogenic, or teratogenic effects. It also has no dependence and drug resistance.

Cimetidine. Its chemical name is: N-methyl-N"-[2[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-N-cyanoguanidine. Molecular formula: C10H16N6S Molecular weight: 252.34

This product is white or light blue or light gray-green tablets with colorants added.

Used to treat duodenal ulcer, gastric ulcer, reflux esophagitis, stress ulcer and Zollinger (Ellison) syndrome.

This drug must be used according to a doctor's prescription. Adults: 1. For the treatment of duodenal ulcer or pathological hypersecretion, take 0.2g to 0.4g once, 2 to 4 times a day, after meals and before bedtime. Or take 0.8g once, before bedtime. 2. For the prevention of ulcer recurrence, take 0.4g once, before bedtime. 3. For patients with renal insufficiency, the dosage is reduced to 0.2g once, once every 12 hours. 4. For elderly patients, the dosage should be reduced as appropriate.

The adverse reactions of this product are generally uncommon and usually disappear after continued use or discontinuation of the drug. 1. The more common adverse reactions are diarrhea, fatigue, dizziness, drowsiness, headache and rash. 2. This product has a mild anti-androgen effect. Larger doses (more than 1.6g per day) can cause male breast development, female galactorrhea, loss of libido, impotence, and decreased sperm count, which disappear after discontinuation of the drug. 3. This product can pass the blood-brain barrier and has certain neurotoxicity. Occasionally, mental disorders, anxiety, depression, worry, delirium, and disorientation are more common in elderly and critically ill patients. Generally, the symptoms disappear 3-4 days after discontinuation of the drug. When treating gastrointestinal complications of alcoholics, delirium tremens may occur, which is similar to alcohol withdrawal syndrome. 4. Rare adverse reactions of this product include: allergic reactions, fever, joint pain, myalgia, interstitial nephritis, urinary retention, liver toxicity, and pancreatitis. 5. Very few patients have leukocytopenia and agranulocytosis. These patients suffer from other serious diseases and receive drugs and treatments known to cause blood cell reduction. Thrombocytopenia and aplastic anemia are rarely reported. Occasionally, plasma creatinine or serum transaminase increases. 6. Bradycardia, tachycardia and heart block are extremely rare when using H2 receptor blockers.

It is contraindicated for pregnant and lactating women.

Precautions for children: Children should use the product under the guidance of a physician. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: Elderly patients should use the product under the guidance of a physician.

1. When used in combination with antacids, it can relieve pain in duodenal ulcers, but the absorption of cimetidine may be reduced, so it is generally not recommended. If it must be used in combination with antacids, the two should be taken at least 1 hour apart. 2. Taking metoclopramide (Metoclopramide) with this product at the same time can reduce the blood concentration of this product, and the dose of this product needs to be appropriately increased. 3. Since sucralfate needs to be hydrolyzed by gastric acid to work, this product inhibits gastric acid secretion. The combination of the two may reduce the efficacy of sucralfate. 4. This product inhibits the oxidative metabolic pathway catalyzed by cytochrome P450 and can reduce hepatic blood flow. Therefore, when it is used in combination with other drugs, this product can reduce the metabolism of other drugs, resulting in enhanced pharmacological activity or toxicity. These drugs include: (1) When used in combination with benzodiazepines for a long time, the metabolism in the liver can be inhibited, resulting in increased blood concentration of the latter, aggravating sedation and other central nervous system inhibitory effects, and may develop into respiratory and circulatory failure. However, lorazepam, oxazepam, and temazepam do not seem to be affected. (2) When used in combination with warfarin and other coumarin anticoagulants, the prothrombin time can be further prolonged. Therefore, it is necessary to pay close attention to changes in the condition and adjust the dosage of anticoagulants. (3) When used in combination with phenytoin sodium or other hydantoins, the latter's blood concentration may increase, leading to phenytoin sodium poisoning. If it must be used in combination, the phenytoin sodium blood concentration should be measured after 5 days to adjust the dosage, and pay attention to regular review of peripheral blood. (4) When used in combination with propranolol, metoprolol, and metronidazole, the blood concentration may increase. (5) When used in combination with xanthine drugs such as theophylline, caffeine, and aminophylline, liver metabolism is reduced, which can lead to delayed clearance and increased blood concentration, and poisoning reactions may occur. (6) This product can increase the absolute bioavailability of verapamil (Isopamil) from 26.3% plus mn; 16.8% to 49.3% plus mn; 23.6%. Since verapamil can cause rare but serious side effects, it should be used with caution. (7) This product can inhibit the metabolism of quinidine. When patients take digoxin and quinidine at the same time, this product should not be used. Because quinidine can displace digoxin from its binding site, the blood concentrations of quinidine and digoxin are increased. At this time, the blood concentration should be monitored. (8) It should be used with caution when used in combination with other intrahepatic metabolites, such as lidocaine and tricyclic antidepressants. 5. When used in combination with opioids, it has been reported that adverse reactions such as respiratory depression, mental confusion, and loss of orientation can occur in patients with chronic renal failure. The dosage of opioid preparations should be reduced for such patients. 6. Since this product increases the pH value of gastric juice, when used in combination with tetracycline, the dissolution rate of tetracycline may decrease, absorption may decrease, and the effect may be weakened (but the hepatic enzyme inhibition of this product may increase the blood concentration of tetracycline); if used in combination with aspirin, the opposite result may occur, and the effect of aspirin may be enhanced. 7. When used in combination with ketoconazole, it may interfere with the absorption of the latter and reduce its antifungal activity, but the above changes can be avoided by taking some acidic beverages at the same time. 8. When used in combination with captopril, this product may cause mental symptoms. 9. Since this product has a myoneural blocking effect similar to that of aminoglycoside antibiotics, this effect cannot be counteracted by neostigmine, but can only be counteracted by calcium chloride. Therefore, when used in combination with aminoglycosides, it may cause respiratory depression or respiratory arrest. (5) When used in combination with xanthine drugs such as theophylline, caffeine, and aminophylline, liver metabolism is reduced, which may lead to delayed clearance, increased blood concentration, and possible poisoning reactions. (6) This product can increase the absolute bioavailability of verapamil (Isopamil) from 26.3% plus mn; 16.8% to 49.3% plus mn; 23.6%. Since verapamil can cause rare but serious side effects, it should be used with caution. (7) This product can inhibit the metabolism of quinidine. When patients take digoxin and quinidine at the same time, this product should not be used. Because quinidine can displace digoxin from its binding site, the blood concentrations of quinidine and digoxin are increased. At this time, the blood concentration should be monitored. (8) It should be used with caution when used in combination with other intrahepatic metabolites, such as lidocaine and tricyclic antidepressants. 5. When used in combination with opioids, it has been reported that adverse reactions such as respiratory depression, mental confusion, and loss of orientation can occur in patients with chronic renal failure. The dosage of opioid preparations should be reduced for such patients. 6. Since this product increases the pH value of gastric juice, when used in combination with tetracycline, the dissolution rate of tetracycline may decrease, absorption may decrease, and the effect may weaken (but the hepatic enzyme inhibition of this product may increase the blood concentration of tetracycline); if used in combination with aspirin, the opposite result will occur, and the effect of aspirin may be enhanced. 7. When used in combination with ketoconazole, it may interfere with the absorption of the latter and reduce its antifungal activity, but the above changes can be avoided by taking some acidic beverages at the same time. 8. This product may cause mental symptoms when used in combination with captopril. 9. Since this product has a myoneural blocking effect similar to that of aminoglycoside antibiotics, this effect cannot be counteracted by neostigmine, but can only be counteracted by calcium chloride. Therefore, when used in combination with aminoglycosides, it may cause respiratory depression or respiratory arrest.

Keep sealed.

0.2 g

36 months

Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd.

• Founded in:

  2000-01-14

• Address:

  Yingshang Industrial Development Zone, Fuyang City, Anhui Province

• Tax NO.:

  91341226738907020P

• Registered Funds:

  30 million yuan

• Email:

  Log in to view